Back to the main directory
Company Analysis / Equity
- ATOS: A pure play biopharma after sale of its diagnostics business by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business, two Phase II clinical programs, and one new clinical program initiated. by Zacks
- ATOS: ATOS enters therapeutic market via acquisition, significant revenue growth from pharmacogenomics testing in 1Q15, which convinces us revenue growth will accelerate in the coming quarters Buy by Zacks
- ATOS: Focused pure play breast care company with huge potential to grow initiating with Outperform by Zacks
- ATOS: Significant revenue growth from Pharmacogenomics testing in 1Q15, which convinces us revenue growth will accelerate in the coming quarters Buy by Zacks
- ATOS: Two Phase II clinical programs, and one new clinical program initiated. A pure play biopharma after sale of its diagnostics business. by Zacks
- ATOS: Two important deals will accelerate revenue growth; there is still enough room for further price appreciation Outperform by Zacks
- initiated an unexpected voluntary recall of its MASCT system and ForeCYTE test moving from Outperform to Neutral by Zacks
- AVIR: 2016 Financial Results; Expecting Multiple Phase 2 Data Readouts in 2H 2016 by Zacks
- AVIR: Resuming Phase 2a RSV Trial by Zacks
- Multiple Shots on Goal; Initiating with $3.30 Target. by Zacks
- Progress made in reimbursement, by Zacks
- Three platform technologies for targeted therapy, diversified pipeline and strong balance sheet - initiating with Outperform by Zacks
- AVIR: Biota Pharmaceuticals is now Aviragen Therapeutics by Zacks
- BCLI: Phase 2 ALS Study a Success as NurOwnâ„¢ Treatment Shows Clinical Benefit by Zacks
- BCLI: Preparing for Multi-dose Phase 2 Trial of NurOwn™ in ALS; Data From Single-dose ALS Trial in the U.S. in mid- 2016… by Zacks
- AVIR: Initiating Coverage by Zacks
- Diversity helps keep group on track by Edison Investment Research
- BCLI: Data From the Phase 2 ALS Trial Expected in Mid-2016 by Zacks
- BCLI: Initiating coverage of BrainStorm Cell Therapeutics, Inc by Zacks
- BCLI: NASDAQ & Fast Track For NurOwn Reinforce Buy Thesis On BrainStorm by Zacks
- BCLI: Phase 2 ALS Trial Fully Enrolled; Data in Mid-2016 by Zacks
- BCLI: Phase 2a ALS Data Coming in The Next Few Weeks by Zacks
- BMRA: Add'l Insight Into High-Potential IBS Product by Zacks
- BMRA: Base Business Bounces Back, InFoods Continues to Attract Who s-Who of IBS by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business, two Phase II clinical programs Buy by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business, two Phase II clinical trial will be initiated soon Buy by Zacks
- ATOS: Better than expected Financials reported for 2014, revenue growth will accelerate in 2015; there is still enough room for further price appreciation Buy by Zacks
- ATOS: Revenue will continue to grow though reimbursement is uncertain for PG test, Two Phase II clinical trial will be initiated soon Buy by Zacks
- ATOS: Significant revenue growth from pharmacogenomics testing in 1H15, which convinces us revenue growth will accelerate in the coming quarters,; ATOS enters therapeutic market via acquisition Buy by Zacks
- ATOS: Two Phase II clinical trial will be initiated soon, revenue growth will accelerate in the coming quarters Buy by Zacks
- Record revenue reported in 2Q13 following national rollout of ForeCYTE, progress made in reimbursement by Zacks
- ATOS: On track to resubmit 510(k) for its MASCT system and ForeCYTE test, waiting for FDA response Neutral by Zacks
- AVIR: Cash-Rich With Three Pivotal Trials Underway; Reports Third Quarter Financial Results by Zacks
- Focused pure play breast health testing company with huge potential to grow initiating with Outperform by Zacks
- National rollout of ForeCYTE is on track, Progress made in reimbursement by Zacks
- Sales is picking up steam in 1Q13 following national rollout of ForeCYTE, progress made in reimbursement by Zacks
- AVIR: AVIR Inked $20 Million Non-Dilutive Royalty Agreement by Zacks
- BCLI: Gearing Up to Start International Phase 3 Trial of NurOwn™ in U.S. and Israel… by Zacks
- BCLI: Planning for Phase 3 Study of NurOwn™ in ALS Following Successful Phase 2 Results… by Zacks
- AVIR: Clinical Programs On Track; Biota Reports Q2 Financial Results. by Zacks
- AVIR: Interim Update by Zacks
- BCLI: DSMB Recommends Phase 2 ALS Trial Continue as Planned; Data in Mid- 2016 by Zacks
- BCLI: Full Phase 2 ALS Data In April; We re Buyers Ahead Of The Release by Zacks
- BCLI: Intriguing data from Phase 2a study by Zacks
- BCLI: Phase 2 ALS Data and First Quarter Financial Update by Zacks
- BCLI: Phase 2 trial in ALS underway by Zacks
- BMRA: Additional Info/Progress of InFoods Prompts Upward Revision to Valuation by Zacks
- BMRA: Attractive Entry Point with BMRA Trading at Book Value by Zacks
- BMRA: More Positive Clarity on InFoods FDA Pathway. Korean Licensing Agreement by Zacks